After the long, grueling path to EUA, Roche says there is a supply shortage of Actemra
Roche’s drug Actemra was granted emergency use authorization by the FDA for Covid-19 despite some mixed data, but an 11,000-patient analysis soon showed it cut the risk of death. Less than two months after that analysis, the company is running out of supply of the drug, and it’s placed the blame on a surge in cases coupled with declining vaccination rates.
There will be a global shortage for “at least the next several weeks,” Genentech said in a press release Monday afternoon. Replenishment is expected by the end of August, but this shortage may not be the only one if infections continue to rage at the current pace, the company added.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.